Stay up to date with the latest in psychedelic news

Press Releases
Press Release
5.6.2021

Cybin to Present at the Benzinga Global Small Cap Conference

Read more >
Press Release
4.26.2021

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Read more >
Press Release
4.21.2021

Cybin Demonstrates Proof of Concept of its Deuterated Tryptamines for the Treatment of Depression and Addiction

Read more >
Press Release
4.19.2021

Cybin to Present at the Bloom Burton & Co. Healthcare Investor Conference

Read more >
Press Release
4.19.2021

Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back

Read more >
Press Release
4.13.2021

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Read more >
Press Release
3.30.2021

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

Read more >
Press Release
3.22.2021

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Read more >
Latest News

More Psychedelic Companies are going Public

THE NASCENT PSYCHEDELIC industry is booming as several companies have gone public and more are expected to follow this route in 2021 to attract more capital from institutional and retail investors.

Read more

Psyched: Cybin Raises CA$45M, Numinus Harvests Legal Mushrooms, Toadstool Enters Psychedelic Space

Read more >

2020 was the Year of Psychedelics, Here's why

Read more >

5 Groovy Psychedelic Stocks to Buy

Read more >
Featured

The Emerging Revival of Psychedelics in Neuroscience

Read more >

Cybin, Bryan Johnson and the Greatest Impact on the Future

Read more >

Horizons CEO Steve Hawkins on Launching the First Psychedelic Stock ETF (PSYK)

Read more >
view all
close

Our site uses cookies. Learn more about our privacy policy.

I accept the use of cookies